|
Name |
Chaetoglobosin G
|
Molecular Formula | C32H36N2O5 | |
IUPAC Name* |
(1R,7E,9S,11E,13R,14S,17R,18S)-14-hydroxy-18-(1H-indol-3-ylmethyl)-7,9,15,16-tetramethyl-19-azatricyclo[11.7.0.01,17]icosa-7,11,15-triene-2,5,6,20-tetrone
|
|
SMILES |
C[C@H]\1C/C=C/[C@H]2[C@@H](C(=C([C@@H]3[C@@]2(C(=O)CCC(=O)C(=O)/C(=C1)/C)C(=O)N[C@H]3CC4=CNC5=CC=CC=C54)C)C)O
|
|
InChI |
InChI=1S/C32H36N2O5/c1-17-8-7-10-23-30(38)20(4)19(3)28-25(15-21-16-33-24-11-6-5-9-22(21)24)34-31(39)32(23,28)27(36)13-12-26(35)29(37)18(2)14-17/h5-7,9-11,14,16-17,23,25,28,30,33,38H,8,12-13,15H2,1-4H3,(H,34,39)/b10-7+,18-14+/t17-,23-,25-,28-,30+,32+/m0/s1
|
|
InChIKey |
COZBDBUQXIMMKP-RWFPWACCSA-N
|
|
Synonyms |
Chaetoglobosin G; CHEBI:68813; Cheatoglobosin G; 65773-98-0; SCHEMBL33632; CHEMBL486257; Q27137191; (1R,7E,9S,11E,13R,14S,17R,18S)-14-hydroxy-18-(1H-indol-3-ylmethyl)-7,9,15,16-tetramethyl-19-azatricyclo[11.7.0.01,17]icosa-7,11,15-triene-2,5,6,20-tetrone; (3S,3aR,6S,6aR,7E,10S,11E,17aR)-6-hydroxy-3-(1H-indol-3-ylmethyl)-4,5,10,12-tetramethyl-3,3a,6,6a,9,10,15,16-octahydro-1H-cyclotrideca[d]isoindole-1,13,14,17(2H)-tetrone
|
|
CAS | NA | |
PubChem CID | 23259924 | |
ChEMBL ID | CHEMBL486257 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 528.6 | ALogp: | 2.6 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 116.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 39 | QED Weighted: | 0.295 |
Caco-2 Permeability: | -4.995 | MDCK Permeability: | 0.00001110 |
Pgp-inhibitor: | 0.99 | Pgp-substrate: | 0.991 |
Human Intestinal Absorption (HIA): | 0.034 | 20% Bioavailability (F20%): | 0.025 |
30% Bioavailability (F30%): | 0.023 |
Blood-Brain-Barrier Penetration (BBB): | 0.044 | Plasma Protein Binding (PPB): | 98.53% |
Volume Distribution (VD): | 0.737 | Fu: | 2.94% |
CYP1A2-inhibitor: | 0.077 | CYP1A2-substrate: | 0.434 |
CYP2C19-inhibitor: | 0.887 | CYP2C19-substrate: | 0.761 |
CYP2C9-inhibitor: | 0.869 | CYP2C9-substrate: | 0.832 |
CYP2D6-inhibitor: | 0.204 | CYP2D6-substrate: | 0.199 |
CYP3A4-inhibitor: | 0.95 | CYP3A4-substrate: | 0.321 |
Clearance (CL): | 6.285 | Half-life (T1/2): | 0.177 |
hERG Blockers: | 0.24 | Human Hepatotoxicity (H-HT): | 0.338 |
Drug-inuced Liver Injury (DILI): | 0.218 | AMES Toxicity: | 0.452 |
Rat Oral Acute Toxicity: | 0.699 | Maximum Recommended Daily Dose: | 0.959 |
Skin Sensitization: | 0.863 | Carcinogencity: | 0.051 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.934 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002443 | 0.815 | D09ZIO | 0.259 | ||||
ENC002442 | 0.785 | D0W7WC | 0.257 | ||||
ENC004465 | 0.722 | D02DMQ | 0.257 | ||||
ENC002680 | 0.709 | D01TSI | 0.255 | ||||
ENC003226 | 0.701 | D0SP3D | 0.249 | ||||
ENC004469 | 0.688 | D09NNH | 0.249 | ||||
ENC002955 | 0.662 | D0V3ZA | 0.249 | ||||
ENC002681 | 0.636 | D01XDL | 0.241 | ||||
ENC004447 | 0.636 | D05EJG | 0.240 | ||||
ENC003245 | 0.621 | D05MQK | 0.239 |